

UC Office of the President

Research Grants Program Office (RGPO) Funded Publications

Title

Mercapturic Acids Derived from the Toxicants Acrolein and Crotonaldehyde in the Urine of Cigarette Smokers from Five Ethnic Groups with Differing Risks for Lung Cancer

Permalink

<https://escholarship.org/uc/item/43r201jm>

Journal

PLOS ONE, 10(6)

ISSN

1932-6203

Authors

Park, Sungshim L
Carmella, Steven G
Chen, Menglan
et al.

Publication Date

2015

DOI

10.1371/journal.pone.0124841

Peer reviewed

RESEARCH ARTICLE

Mercapturic Acids Derived from the Toxicants Acrolein and Crotonaldehyde in the Urine of Cigarette Smokers from Five Ethnic Groups with Differing Risks for Lung Cancer

Sungshim L. Park¹, Steven G. Carmella², Menglan Chen², Yesha Patel¹, Daniel O. Stram¹, Christopher A. Haiman¹, Loic Le Marchand³, Stephen S. Hecht^{2*}

1 Department of Preventive Medicine, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California, United States of America, **2** Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States of America, **3** University of Hawaii Cancer Center, Honolulu, Hawaii, United States of America

* hecht002@umn.edu



OPEN ACCESS

Citation: Park SL, Carmella SG, Chen M, Patel Y, Stram DO, Haiman CA, et al. (2015) Mercapturic Acids Derived from the Toxicants Acrolein and Crotonaldehyde in the Urine of Cigarette Smokers from Five Ethnic Groups with Differing Risks for Lung Cancer. *PLoS ONE* 10(6): e0124841. doi:10.1371/journal.pone.0124841

Academic Editor: Max Costa, New York University School of Medicine, UNITED STATES

Received: January 26, 2015

Accepted: March 17, 2015

Published: June 8, 2015

Copyright: © 2015 Park et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All data are available at the NIH dbGaP database. The Study Accession number is phs000220.v1.p1. Any additional data requests should be made to Loic Le Marchand (loic@cc.hawaii.edu), principal investigator of the Multiethnic Cohort study.

Funding: This study was supported by grant no. CA-138338 and in part by grant no. CA-14089 from the U.S. National Cancer Institute (<http://www.cancer.gov>). Mass spectrometry was carried out in the Analytical Biochemistry Shared Resource of the

Abstract

The Multiethnic Cohort epidemiology study has clearly demonstrated that, compared to Whites and for the same number of cigarettes smoked, African Americans and Native Hawaiians have a higher risk for lung cancer whereas Latinos and Japanese Americans have a lower risk. Acrolein and crotonaldehyde are two important constituents of cigarette smoke which have well documented toxic effects and could play a role in lung cancer etiology. Their urinary metabolites 3-hydroxypropylmercapturic acid (3-HPMA) and 3-hydroxy-1-methylpropylmercapturic acid (HMPMA), respectively, are validated biomarkers of acrolein and crotonaldehyde exposure. We quantified levels of 3-HPMA and HMPMA in the urine of more than 2200 smokers from these five ethnic groups, and also carried out a genome wide association study using blood samples from these subjects. After adjusting for age, sex, creatinine, and total nicotine equivalents, geometric mean levels of 3-HPMA and HMPMA were significantly different in the five groups ($P < 0.0001$). Native Hawaiians had the highest and Latinos the lowest geometric mean levels of both 3-HPMA and HMPMA. Levels of 3-HPMA and HMPMA were 3787 and 2759 pmol/ml urine, respectively, in Native Hawaiians and 1720 and 2210 pmol/ml urine in Latinos. These results suggest that acrolein and crotonaldehyde may be involved in lung cancer etiology, and that their divergent levels may partially explain the differing risks of Native Hawaiian and Latino smokers. No strong signals were associated with 3-HPMA in the genome wide association study, suggesting that formation of the glutathione conjugate of acrolein is mainly non-enzymatic, while the top significant association with HMPMA was located on chromosome 12 near the *TBX3* gene, but its relationship to HMPMA excretion is not clear.

Masonic Cancer Center, supported in part by National Cancer Institute Cancer Center Support grant no. CA-77598.

Competing Interests: The authors have declared that no competing interests exist.

Introduction

Lung cancer is the leading cause of cancer death in the world, responsible for 1,590,000 deaths in 2012, about 4400 per day [1]. Cigarette smoking is the cause of approximately 80% of this mind-boggling death toll in males and at least 50% in females [2]. Decreasing the prevalence of cigarette smoking is one proven approach to lung cancer prevention; a goal would be to return lung cancer to the category of a relatively rare disease, as it was early in the 20th century [3]. But the world has 1.25 billion smokers [4], whose nicotine addiction is eagerly fed and supported by tobacco companies with massive financial resources, so it does not appear that this goal will be reached in the near future. In the meantime, it is important to understand factors that dictate susceptibility to lung cancer, so that alternative preventive measures can be devised.

One clue to a better understanding of lung cancer susceptibility is different risks among smokers in varied ethnic groups. Thus, investigators in the Multi-ethnic Cohort (MEC) Study found that, for the same quantity of cigarettes smoked, African Americans and Native Hawaiians were at greater risk for lung cancer than Whites while Latinos and Japanese Americans were less susceptible [5]. These differences were evident in men and women and for all histologic types of lung cancer. The differences in susceptibility were most pronounced at lower numbers of cigarettes smoked per day, and were not observed in non-smokers. Many studies comparing lung cancer risk between specific ethnic groups have produced similar results [6–15].

Our working hypothesis is that differences in the uptake and metabolism of pulmonary carcinogens and toxicants in tobacco smoke are responsible, at least in part, for the observed variation in lung cancer risk. We are exploring this hypothesis by analyzing tobacco smoke constituents and their metabolites in the urine of subjects from the five ethnic groups noted above in tandem with a genome wide association study (GWAS). In studies completed so far, we have reported differences in levels of nicotine and its metabolites as well as metabolites of the tobacco-specific lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in these five ethnic groups and have examined the relationship of nicotine metabolites to GWAS signals on chromosome 4, specifically variants in *UGT2B10* [16–18]. In the study presented here, we have explored the possible roles of acrolein and crotonaldehyde by analysis of their metabolites 3-hydroxypropyl mercapturic acid (3-HPMA) and 3-hydroxy-1-methylpropylmercapturic acid (HMPMA), respectively, in urine [19,20]. Structures of these compounds are shown in Fig 1. 3-HPMA and HMPMA are formed by conjugation of acrolein and crotonaldehyde respectively with cellular glutathione, followed by metabolism of the glutathione conjugates and excretion in urine.




Fig 1. Structures of acrolein, crotonaldehyde, 3-HPMA, and HMPMA.

doi:10.1371/journal.pone.0124841.g001

Both acrolein and crotonaldehyde are intense eye and respiratory tract irritants [21,22]. Consistently, inhalation studies of acrolein in laboratory animals demonstrate a variety of toxic effects including irritation, inflammation, cell proliferation, squamous metaplasia and other effects [21]. The irritant properties of crotonaldehyde are also well established [22]. Both acrolein and crotonaldehyde react with DNA to form cyclic 1,*N*²-deoxyguanosine adducts and related structures [23,24]. The cyclic adducts have been detected in lung tissue from smokers [25,26], and the DNA binding pattern of acrolein in the *p53* tumor suppressor gene is similar to the pattern of mutational hotspots in *p53* found in lung tumors from smokers [27]. There is debate about the role of acrolein in lung carcinogenesis by cigarette smoke, as there is little evidence for its carcinogenicity in laboratory animals [21,28]. The irritant and inflammatory properties of both of these α,β -unsaturated aldehydes, along with the *p53* data for acrolein, indicate that they may play a role in lung carcinogenesis in smokers. In view of these facts, we have analyzed HPMA and HMPMA in the urine of self-identified African Americans, Native Hawaiians, Whites, Latinos, and Japanese Americans, all of whom were regular cigarette smokers. A GWAS in search of common genetic variants possibly predictive of 3-HPMA and HMPMA levels in these subjects was also conducted.

Materials and Methods

Subjects

Approval for this study, including the consent procedure, was obtained from the Institutional Review Boards of the University of Minnesota, the University of Hawaii, and the University of Southern California. Study participants provided written consent. IRB Code Number: 0912M75654. Subjects took part in the MEC, a prospective cohort study investigating the association of genetic and lifestyle factors with chronic diseases in a population with diverse ethnic backgrounds [29]. The cohort consists of 215,251 men and women, ages 45 to 75 at baseline, belonging mainly to the following five ethnic/racial groups: African Americans, Native Hawaiians, Whites, Latinos, and Japanese Americans. Potential participants were identified between 1993 and 1996 in Hawaii and California (mainly Los Angeles County) through voter registration lists, drivers' license files, and Health Care Financing Administration data. Each participant completed a self-administered questionnaire which was delivered by mail and inquired about demographic, dietary, lifestyle, and other exposure factors.

This specific study was carried out in a subgroup of the MEC participants who were current smokers and were cancer-free at the time of urine collection. Thus, about 10 years after their entry into the cohort, 2,393 of this subgroup participated in the MEC bio-specimen sub-cohort and provided a blood sample and a first morning urine sample (subjects recruited in California) or overnight urine sample (subjects recruited in Hawaii), and completed an epidemiologic questionnaire, smoking history questionnaire and medication record. The overnight urine sample was collected starting between 5 pm and 9 pm (depending on the subject). This sample includes all urine passed during the night as well as the first morning urine. All urine was kept on ice until processing. Aliquots were subsequently stored in a -80°C freezer until analysis. The overnight or first morning urine was used to measure 3-HPMA and HMPMA.

Analysis of 3-HPMA and HMPMA

This was performed using a 96-well high throughput LC-MS/MS method, as described previously [30]. Detection limits were 4.5 pmol/ml for 3-HPMA and 3.5 pmol/ml for HMPMA. Accuracy was 92% for 3-HPMA and 97% for HMPMA. Inter-day precision was 9.1% [coefficient of variation (CV)] for 3-HPMA and 11.0% for HMPMA. Among blind duplicates included

among the samples, there were inter-batch CVs of 18.9% for 3-HPMA and 19.6% for HMPMA while the intra-batch CVs were 9.2% and 7.7% for the respective metabolites.

Total nicotine equivalents

Total nicotine equivalents, the sum of nicotine and its metabolites nicotine glucuronide, cotinine, cotinine glucuronide, 3'-hydroxycotinine, 3'-hydroxycotinine glucuronide, and nicotine *N*-oxide, were determined as described previously [16]. These data have been published [16], and were used here for statistical adjustments of the 3-HPMA and HMPMA data.

Creatinine Analysis

Creatinine was analyzed using a colorimetric microplate assay (CRE34-K01) purchased from Eagle Bioscience (<http://stores.eaglebio.com/creatinine-microplate-assay-kit>).

Statistical methods

For this analysis, 2,291 subjects were retained. These subjects had total nicotine equivalents >1.27 nmol/ml (4-times the limit of quantitation) [16] and had either 3-HPMA or HMPMA measured. Of the 2,291 subjects, nine subjects were missing measures of 3-HPMA and seven subjects were missing measures of HMPMA.

Additionally, among the subjects retained for this analysis, 11 participants were missing BMI and 42 participants had missing values for cigarettes per day (CPD) at the time of urine collection. Using the Markov Chain Monte Carlo method and PROC MI statement from the SAS v9.2 software (SAS institute, Cary, NC) [31], the missing values for BMI and CPD were imputed. The imputed values were based on age at cohort entry, race/ethnicity, time between cohort entry and time of urine collection, BMI at baseline or number of CPD at baseline and smoking duration (for missing CPD). Ten datasets were created for the imputed missing values and the mean values across all 10 datasets were used to replace the missing measures.

To examine the correlation between 3-HPMA, HMPMA and measures of smoking (CPD and total nicotine equivalents), Pearson's partial correlation coefficients (r) were adjusted for age, sex and race/ethnicity and creatinine levels (natural log). To compare the rank of 3-HPMA and HMPMA levels across race/ethnicity, the Wilcoxon Mann-Whitney test was employed. Also, the covariate-adjusted geometric means for 3-HPMA and HMPMA were computed for each ethnic/racial group at the mean covariate vector. We used two multivariable linear models. The first adjusted for the following predictors: age at time of urine collection (continuous), sex, race, and creatinine levels (natural log) and the second additionally adjusted for total nicotine equivalents. We also examined whether other factors such as BMI were associated with 3-HPMA and HMPMA. To better meet model assumptions, 3-HPMA and HMPMA were transformed by taking the natural log. For ease of interpretation, the values presented in the tables were back-transformed as geometric means to their natural scale.

GWAS methods

A total of 2,418 current smokers were genotyped using the Illumina Human1M-Duo BeadChip (1,199,187 SNPs), as previously described [17]. Imputation of the variants included in the 1000 Genomes Project (<http://www.1000genomes.org/>) was performed using SHAPEIT [32] and IMPUTE2 [33] using a cosmopolitan reference panel (all groups included). After imputation with IMPUTE2 we used SNPs with an IMPUTE2 info score of ≥ 0.30 and minor allele frequency (MAF) >1% in any MEC ethnic group in our association testing. For 3-HPMA and HMPMA, a total of 2,211 and 2,213 study participants, respectively, with complete genotype

Table 1. Main characteristics of study participants^a stratified by race/ethnicity.

	African Americans		Native Hawaiians		Whites		Latinos		Japanese Americans		p-values
	Median (Interquartile)										
All	n = 363		n = 329		n = 441		n = 454		n = 704		
Age (years)	64	(59–69)	60	(56–65)	62	(58–68)	65	(61–70)	62	(58–69)	<0.0001
BMI (kg/m ²)	26.9	(23.4–30.7)	26.8	(24.2–30.8)	24.7	(22.0–28.0)	26.5	(24.1–29.8)	24.4	(21.9–27.0)	<0.0001
Creatinine (mg/dl)	89	(54–142)	60	(38–91)	54	(33–85)	77	(50–117)	55	(34.0–88.5)	<0.0001
Cigarettes per day	10	(5–15)	15	(8–20)	20	(10–20)	7.1	(4–12)	12	(9–20)	<0.0001
Total nicotine equivalents (nmol/ml)	44.4	(27.4–74.1)	31.3	(20.0–48.0)	36.3	(22.0–61.1)	32.5	(20.9–53.6)	27.2	(15.8–43.5)	<0.0001
Males	n = 111		n = 120		n = 191		n = 238		n = 402		
Age (years)	63	(58–66)	63	(58–68)	62	(59–67)	65	(62–71)	62	(58–68)	<0.0001
BMI (kg/m ²)	26.4	(23.1–28.5)	26.8	(24.3–30.6)	25.8	(23.3–28.7)	25.8	(23.7–28.7)	24.8	(22.7–27.4)	<0.0001
Creatinine (mg/dl)	124	(81.5–167)	75	(50.5–124.4)	71	(47–108)	90.5	(58.1–135)	70	(43.1–105)	<0.0001
Cigarettes per day	10	(6.301–20)	18.5	(10–20)	20	(15–25)	10	(5–15)	15	(10–20)	<0.0001
Total nicotine equivalents (nmol/ml)	54.4	(32.0–92.8)	33.4	(22.2–52.0)	41.2	(24.6–78.4)	35.0	(21.9–59.1)	30.0	(17.9–47.6)	<0.0001
Females	n = 252		n = 209		n = 250		n = 216		n = 302		
Age (years)	64	(59–71)	59	(56–64)	62	(58–69)	64.5	(60–69)	62	(58–69)	<0.0001
BMI (kg/m ²)	27.4	(23.5–31.5)	26.8	(24.0–31.1)	23.9	(21.0–28.0)	27.1	(24.2–30.6)	23.5	(20.6–26.6)	<0.0001
Creatinine (mg/dl)	79.5	(48.3–126.5)	54	(33–79)	47	(29–67)	64.5	(44.8–93.5)	43.738	(28.0–66.2)	<0.0001
Cigarettes per day	10	(5–15)	12	(8–20)	15	(8–20)	6	(4.0–10)	10	(7–15)	<0.0001
Total nicotine equivalents (nmol/ml)	41.4	(26.0–66.3)	30.1	(19.3–45.3)	32.1	(20.5–50.7)	31.7	(18.5–50.3)	22.3	(13.7–35.6)	<0.0001

^a Includes never married, separated, widowed, and divorced.

doi:10.1371/journal.pone.0124841.t001

and phenotype data, and 11,892,802 SNPs/indels (1,131,426 genotyped and 10,761,376 imputed) were included in the analysis. In the genetic analyses we adjusted for principal components, race, sex, age, creatinine and total nicotine equivalents, and enforced criteria of 5×10^{-8} for genome wide significance.

Results

Characteristics of the subjects in this study are summarized in [Table 1](#). Median ages in the 5 ethnic groups ranged from 60–64 years, BMI from 24.4–26.9 kg/m³, creatinine from 54–89 mg/dL, cigarettes per day from 7.1–20, and total nicotine equivalents from 27.2–44.4 nmol/mL. Males comprised 30.6% of the African Americans, 36.5% of the Native Hawaiians, 43.3% of the Whites, 51.5% of the Latinos, and 57.1% of the Japanese Americans. In all groups, males smoked more cigarettes per day than females, and males had higher levels of total nicotine equivalents than females in all five ethnic groups.

Correlations among cigarettes per day, total nicotine equivalents, and levels of 3-HPMA and HMPMA are summarized in [Table 2](#). All correlations were significant ($p < 0.0001$). The

Table 2. Pearson's correlation between measures of smoking and 3-HPMA and HMPMA.^a

	All N = 2221			Males N = 1031			Females N = 1190				
	CPD	TNE	3-HPMA	CPD	TNE	3-HPMA	CPD	TNE	3-HPMA		
TNE	0.5			TNE	0.49		TNE	0.51			
p-value	<0.0001			p-value	<0.0001		p-value	<0.0001			
3-HPMA	0.32	0.53		3-HPMA	0.34	0.52	3-HPMA	0.31	0.53		
p-value	<0.0001	<0.0001		p-value	<0.0001	<0.0001	p-value	<0.0001	<0.0001		
HMPMA	0.35	0.58	0.85	HMPMA	0.37	0.6	0.83	HMPMA	0.33	0.58	0.86
p-value	<0.0001	<0.0001	<0.0001	p-value	<0.0001	<0.0001	<0.0001	p-value	<0.0001	<0.0001	<0.0001

^a Abbreviations. CPD, cigarettes per day; TNE, total nicotine equivalents; 3-HPMA, 3-hydroxypropylmercapturic acid; HMPMA, 3-hydroxy-1-methylpropylmercapturic acid

doi:10.1371/journal.pone.0124841.t002

strongest correlations were between 3-HPMA and HMPMA, $r = 0.83\text{--}0.86$, while correlations between total nicotine equivalents and the mercapturic acid levels were somewhat weaker, $r = 0.52\text{--}0.6$. Similar correlation coefficients were obtained when analyzed by ethnic group or gender, in all cases significant ($p < 0.0001$).

Medians and interquartile ranges for levels of 3-HPMA and HMPMA, expressed as pmol/ml urine, are summarized in [Table 3](#). For both 3-HPMA and HMPMA, levels of these metabolites were highest and not significantly different among African Americans, Native Hawaiians, and Whites, whereas Latinos and Japanese Americans had significantly lower levels. The data are stratified by sex in [S1 Table](#). Within each sex, the same trend was observed when comparing the ethnic groups. The relatively high values of 3-HPMA and HMPMA in Native Hawaiians were not due to outliers because they remained after removing the bottom and top 1% of both the total nicotine equivalents and mercapturic acid values. We also observed that levels of both 3-HPMA and HMPMA were significantly higher in males than in females in all ethnic groups ([S1 Table](#)). When expressed per total nicotine equivalents, 3-HPMA levels were highest in Native Hawaiians and Japanese Americans, and HMPMA was highest in Native Hawaiians ([Table 3](#)). When expressed per total nicotine equivalents, 3-HPMA and HMPMA levels were significantly higher in males than females in all ethnic groups ($p < 0.01$) except HMPMA in Latinos ($p = 0.14$) ([S1 Table](#)).

Medians and interquartile ranges for levels of 3-HPMA and HMPMA, expressed per mg creatinine, are summarized in [Table 3](#). Levels of 3-HPMA and HMPMA were highest in Whites and Native Hawaiians, with significantly lower levels in African Americans, Latinos, and Japanese Americans. The lower levels in African Americans when expressed in this manner are due to the significantly higher levels of creatinine in this group ([Table 1](#)).

Geometric means of 3-HPMA and HMPMA in the five ethnic groups are presented in [Table 4](#). In Model 1, they have been adjusted for age, sex, and creatinine. For both 3-HPMA and HMPMA, the highest levels were in Whites and Native Hawaiians, with significantly lower levels in African Americans, Japanese Americans, and Latinos. The lowest levels of both mercapturic acids were in Latinos, and these were significantly lower than in all other groups. Model 2 was additionally adjusted for total nicotine equivalents; the results were similar to those in Model 1, except that the differences between the Latinos and African Americans were no longer significant for either mercapturic acid, and the difference in 3-HPMA levels in the Japanese Americans and Whites was no longer significant. These results are illustrated graphically in [Fig 2](#).

In the GWAS analysis of 3-HPMA and HMPMA we observed little evidence of inflation in the test statistic in the overall multiethnic sample ($\lambda = 1.0$; [S1](#) and [S2 Figs](#)) or in any single

Table 3. Median and interquartile range for measures of 3-HPMA and HMPMA.

	N	Median	(Interquartile range)	p-value ^a when compared to whites
3-HPMA (pmol/ml)				
African Americans	362	3648	(1699–7328)	0.96
Native Hawaiians	329	3736	(2022–6526)	0.78
Whites	438	3548	(1949–6757)	
Latinos	449	2528	(1263–4855)	<0.0001
Japanese Americans	704	2955	(1568–5353)	0.002
p-value			<0.0001	
HMPMA (pmol/ml)				
African Americans	361	2948	(1418–5194)	0.16
Native Hawaiians	329	2766	(1473–4493)	0.67
Whites	440	2535	(1423–4492)	
Latinos	452	1986	(1079–3602)	<0.0001
Japanese Americans	702	2134	(1037–3507)	<0.0001
p-value			<0.0001	
3-HPMA/TNE^b (10³)				
African Americans	362	80.90	(48.35–125.3)	<0.0001
Native Hawaiians	329	111.7	(83.58–150.4)	0.008
Whites	438	101.6	(70.89–143.6)	
Latinos	449	83.36	(54.83–125.5)	<0.0001
Japanese Americans	704	111.5	(77.76–169.0)	0.008
p-value			<0.0001	
HMPMA/TNE (10³)				
African Americans	361	63.66	(41.35–92.47)	<0.0001
Native Hawaiians	329	82.35	(62.13–113.5)	0.009
Whites	440	75.69	(53.21–106.6)	
Latinos	452	64.12	(43.14–96.39)	0.0002
Japanese Americans	702	78.86	(54.80–109.2)	0.49
p-value			<0.0001	
3-HPMA (pmol/mg creatinine)				
African Americans	362	4123	(2341–6808)	<0.0001
Native Hawaiians	329	6007	(3947–9606)	0.19
Whites	438	6738	(3885–1057)	
Latinos	449	3480	(1864–5908)	<0.0001
Japanese Americans	704	5344	(3163–8596)	<0.0001
p-value			<0.0001	
HMPMA (pmol/mg creatinine)				
African Americans	361	3240	(1886–5285)	<0.0001
Native Hawaiians	329	4404	(2753–6780)	0.1
Whites	440	4757	(3101–7215)	
Latinos	452	2613	(1526–4566)	<0.0001
Japanese Americans	702	3591	(2183–5513)	<0.0001
p-value			<0.0001	

^a p-value calculated using Wilcoxon Mann-Whitney test.

^b TNE, total nicotine equivalents.

doi:10.1371/journal.pone.0124841.t003

Table 4. Geometric means (95% CIs) of 3-HPMA and HMPMA, stratified by race/ethnicity.

	N	Model 1				Model 2				
		Geometric means	(95% CI)			Geometric means	(95% CI)			
3-HPMA (pmol/ml)										
African Americans	362	2623	(2403–2864)†	§	*	y	2406	(2226–2600)†	§	y
Native Hawaiians	329	3689	(3373–4035) ‡	‡	*	y	3787	(3499–4099) ‡	‡	* y
Whites	438	3985	(3690–4304) ‡	‡	*	y	3549	(3314–3801) ‡	‡	*
Latinos	449	2087	(1933–2253)†	‡	§	y	2210	(2066–2365)†	§	y
Japanese Americans	704	3142	(2956–3340)†	‡	§	*	3369	(3191–3557) ‡	‡	§ *
p-value**			<0.0001					<0.0001		
HMPMA (pmol/ml)										
African Americans	361	2024	(1865–2196)†	§	*		1860	(1733–1997)†	§	y
Native Hawaiians	329	2689	(2474–2922) ‡	‡	*	y	2759	(2567–2965) ‡	‡	* y
Whites	440	2856	(2659–3068) ‡	‡	*	y	2541	(2388–2705) ‡	‡	* y
Latinos	452	1624	(1513–1743)†	‡	§	y	1720	(1618–1829)†	§	y
Japanese Americans	702	2108	(1992–2232)†	§	*		2259	(2150–2373)†	‡	§ *
p-value**			<0.0001					<0.0001		

Model 1, adjusted for age, sex, creatinine

Model 2, additionally adjusted for total nicotine equivalents

† significant when compared to whites

‡ significant when compared to African Americans

§ significant when compared to Native Hawaiians

* significant when compared to Latinos

y significant when compared to Japanese Americans

** global p-value

doi:10.1371/journal.pone.0124841.t004

ethnic group ($0.95 \leq \lambda's \leq 1.0$) for either phenotype. There were no globally significant variants for the overall results for 3-HPMA using our genomic threshold of $p < 5 \times 10^{-8}$ (S2 Table). The overall results for HMPMA showed a total of nine globally significant variants (p-values ranged from 4.3×10^{-8} to 9.7×10^{-10}) on seven different chromosomes; all of these SNPs are common in African Americans, two are also common in Whites and two others in Latinos (S3 Table). The top significant association, rs55922880 (chr12), is located near gene *TBX3*, a gene involved in encoding transcription factors. Together, these nine variants explain only 5.4% of variability in HMPMA overall, but when observed by ethnic group, they explain 15.8% in African Americans, 11.7% in Latinos followed by 2.8% in Native Hawaiians and 2.1% in Whites with the least variability explained in the Japanese Americans at 1.4%.

In ethnic specific analyses for both phenotypes there were widely scattered associations that were often difficult to interpret due to very low minor allele frequencies (S4, S5, S6, S7, S8, S9, S10, S11, S12, S13 Tables). Of the nine overall significant variants for HMPMA, only one (rs7675915) was also found to be globally significant in the ethnic specific analysis (among Latinos at 2.95×10^{-8}). However, all of the associations tended to be consistent by the different ethnic groups.

Discussion

The urine samples in this study have been previously analyzed for total nicotine equivalents and total NNAL [16,18]. Total nicotine equivalents is an excellent indicator of nicotine dose in

smokers [34]. Total NNAL (the sum of free NNAL and its glucuronides) correlates with total nicotine equivalents [18]. Free NNAL and NNAL glucuronides are metabolites of the potent tobacco-specific lung carcinogen NNK [35]. Free NNAL is itself a powerful lung carcinogen [36,37]. In these studies, median levels of total nicotine equivalents and total NNAL, expressed per ml urine, were highest in African Americans, intermediate in Whites, and lowest in Japanese Americans, and these differences were significant [16,18]. This order of total nicotine equivalents and total NNAL concentrations is consistent with the lung cancer risk for African Americans (highest), Whites (intermediate), and Japanese Americans (lowest) [5]. But the data for Native Hawaiians and Latinos in those two studies did not reflect their lung cancer risk. Native Hawaiians had significantly lower levels of total nicotine equivalents and total NNAL than Whites, when expressed as medians per ml urine, and Latinos had levels the same as Whites [16,18]. The results of the study reported here, in Model 2 (Table 4 and Fig 2), demonstrate that Native Hawaiians had the highest levels of the acrolein and crotonaldehyde metabolites 3-HPMA and HMPMA among the five ethnic groups, and these were statistically indistinguishable from those of Whites, and significantly higher than those of the other groups. Collectively, our results to date thus suggest that acrolein and crotonaldehyde may play some role in the relatively high lung cancer risk of Native Hawaiians. Furthermore, the relatively low levels of 3-HPMA and HMPMA in Latinos are also consistent with their lower lung cancer risk.




Fig 2. Geometric means of A. 3-HPMA and B. HMPMA in the five ethnic groups, after adjusting for age, sex, creatinine, and total nicotine equivalents.

doi:10.1371/journal.pone.0124841.g002

All humans have 3-HPMA and HMPMA in their urine because acrolein and crotonaldehyde are ubiquitous environmental and dietary constituents as well as being products of endogenous metabolism. Levels of 3-HPMA are typically about 4–10 times higher in the urine of smokers than non-smokers and they decrease rapidly and significantly when people stop smoking [19,38–43]. Similar findings pertain to HMPMA but fewer studies have been reported [19,40,41,44]. Cigarette mainstream smoke typically contains 5–60 µg of acrolein per cigarette, and these levels as well as those of nicotine correlate with “tar” in the same brands [45]; less data are available for crotonaldehyde. “Mouth level exposure” to acrolein in cigarette smokers, as determined in cigarettes with increasing deliveries of acrolein, is highly correlated with 3-HPMA in urine [46]. Similarly, mouth level exposure to nicotine is highly correlated with nicotine equivalents in urine [46]. Furthermore, in our study and in a large population based study, total nicotine equivalents in urine correlated with 3-HPMA in urine [47]. Collectively, these observations indicate that acrolein and nicotine in cigarette smoke as well as total nicotine equivalents in urine are strong determinants of 3-HPMA in urine. The Native Hawaiians in our study seem to represent an exception to this generality as their total nicotine equivalents were significantly lower than those of African Americans ($p < 0.0001$) or Whites ($p = 0.0145$) [16], yet their 3-HPMA levels were as high as those of African Americans and Whites. This suggests that there is an important source of acrolein exposure in Native Hawaiians, either exogenous or endogenous, other than cigarette smoke, that contributes to their relatively high levels of urinary 3-HPMA and possibly to lung cancer risk. Similar considerations would presumably apply to HMPMA. We do not have data on the types of cigarettes smoked by the Native Hawaiians in this study, nor do we have data on 3-HPMA or HMPMA in Native Hawaiian non-smokers compared to non-smokers from other ethnic groups. Such data could possibly provide further insight into their 3-HPMA levels.

Previous studies have clearly established the presence of 3-HPMA in the urine of all non-smokers, but the levels can be variable [19]. In one study, a non-smoker group had levels of 3-HPMA which were more than 5 times higher than those reported in some large studies of smokers, indicating important sources of acrolein exposure other than tobacco smoke, but these were not identified [48]. Forest fires, urban fires, automobile exhaust, cooking fumes, and other sources of incomplete combustion including industrial emissions are among the environmental sources of acrolein [21,49–51]. It has also been detected in certain foods and beverages such as coffee and tea [21] and is produced in the body during lipid peroxidation, amino acid metabolism, and polyamine metabolism [52]. Sources of exposure to crotonaldehyde are similar to those of acrolein, and there is convincing evidence from studies of DNA adducts that crotonaldehyde is formed endogenously in humans [22,53,54].

The toxic effects of acrolein, an intensely irritating compound with a disagreeable acrid and pungent odor, are well documented [21,49]. Inhalation of acrolein causes severe respiratory distress and a wide variety of toxic effects in laboratory animals including toxicity to cilia, depressed respiratory rate, weight loss, inflammation, immunosuppression, cell proliferation, and various histopathological changes in the respiratory tract [21,49,52,55]. Acrolein reacts easily with critical proteins such as thioredoxin reductase in bronchial epithelial cells, resulting in dysregulation of cellular oxidative balance and related effects [56–58]. It also inhibits acetylation of aromatic amines and nucleotide excision repair [59,60]. Carcinogenicity studies of acrolein alone have been uniformly negative [21]. One study demonstrated a significantly increased incidence of bladder tumors in rats treated by i.p. injection with acrolein followed by dietary uracil [21]. In spite of these relatively negative carcinogenicity data in laboratory animals, which might be partly a consequence of acrolein’s toxicity, a possible role of acrolein in cigarette smoke-induced lung cancer has emerged from studies of its interactions with the *p53* tumor suppressor gene which mirror those found in lung tumors from smokers [27]. Acrolein

is known to form exocyclic 1,*N*²-deoxyguanosine adducts in DNA [23]. The mutagenicity of these adducts varies from none to moderate [24]. Multiple studies have detected acrolein-DNA adducts in human tissues or cells, including oral cells, colon cells, leukocytes, bladder mucosa, and lung, but there is presently no evidence that these adduct levels are higher in the lungs of smokers than non-smokers [26,61–64]. Collectively, these studies suggest a possible genotoxic role for acrolein in lung cancer induced by cigarette smoke, but this hypothesis has gaps. Acrolein could also contribute to lung cancer etiology by increasing inflammation in the lung [55], thus acting as a co-carcinogen by enhancing the consequences of DNA damage by carcinogens in tobacco smoke.

Crotonaldehyde, like acrolein, is a potent irritant to the respiratory tract and eyes. It caused preneoplastic lesions and a low incidence of neoplastic nodules and hepatocellular carcinoma in rats when administered in the drinking water [65]. Crotonaldehyde forms mutagenic cyclic 1,*N*²-deoxyguanosine adducts in DNA [23,24,66], similar to those produced from acrolein, and these have been detected in human lung as well as other tissues [22,25,53,54].

Presumably, inhalation would be the relevant route of exposure for most of the effects discussed here, although it is possible that endogenous processes in the lung associated with the toxic effects of smoking could result in local generation of acrolein or crotonaldehyde. For example, oxidation of ω -3 fatty acids produces acrolein [67,68]; it is possible that oxidants in cigarette smoke interact with ω -3 fatty acids in the lung resulting in local formation of acrolein. There could also be unrecognized dietary or endogenous sources of acrolein and crotonaldehyde.

We observed higher levels of 3-HPMA and HMPMA in the urine of male than in female smokers, consistent with previously reported results of some [47], but not all studies of 3-HPMA [48]. Higher levels of a number of biomarkers including total nicotine equivalents in the urine of male smokers compared to female smokers have been observed in multiple previous studies, reflecting differences in smoking topography [47,69–71]. However, in our study, levels of 3-HPMA and HMPMA were higher in males than in females even after correcting for total nicotine equivalents. Consistent with the discussion above, this suggests that there is another source of acrolein and crotonaldehyde exposure which is greater in males than in females.

The relatively low levels of 3-HPMA and HMPMA in Latinos is also worth noting, as it is consistent with their relatively low lung cancer risk, in contrast to our previous observations of total nicotine equivalents and total NNAL in this group which were not significantly different from those of Whites. However, we also note that the Japanese-Americans levels of 3-HPMA in Model 2 (Table 4, Fig 2) are statistically indistinguishable from those of Whites, and this does not correlate with their lung cancer risk.

We did not observe a significant signal in the GWAS in search of common genetic variants associated with urinary levels of 3-HPMA in our population. Acrolein is known to be an excellent substrate for GSTP1 with K_{cat}/K_m values of 92–350 $\text{mM}^{-1}\cdot\text{s}^{-1}$ while GSTM1-1 and GSTA1-1 have less catalytic activity [72–74]. The K_{cat}/K_m values for catalysis of glutathione conjugation of crotonaldehyde by these enzymes are less than 1/10th those of acrolein [73,74]. The *GSTP1* gene, located on chromosome 11q13, is a polymorphic gene encoding variant proteins with moderate activities for catalysis of acrolein conjugation [74]. *GSTP*-null mice suffered increased bladder damage upon treatment with cyclophosphamide, which releases acrolein as a metabolite, although the overall excretion of 3-HPMA in these mice was unchanged [75]. Based on these data collectively, we might have expected to see a signal on chromosome 11, particularly in association with 3-HPMA, but this was not observed. We did see significant variants associated with HMPMA, with the strongest association on chromosome 12 (rs 55922880), located near the gene *TBX3*, but the relationship of this gene to crotonaldehyde

metabolism is not clear at present. Overall, the results suggest that the formation of the glutathione conjugates of acrolein and crotonaldehyde that are metabolized to urinary 3-HPMA and HMPMA is mainly a non-enzyme catalyzed process. The uncatalyzed reactions of acrolein and crotonaldehyde with glutathione and related sulfhydryl compounds are well established [52,72].

In summary, the results of this study provide some intriguing new leads with respect to the possible role of the α,β -unsaturated toxicants acrolein and crotonaldehyde in lung cancer etiology in smokers. The relatively high levels of the acrolein and crotonaldehyde biomarkers 3-HPMA and HMPMA in the urine of Native Hawaiians, compared to the other groups in the MEC, is particularly interesting. Further studies are required to investigate endogenous or exogenous exposures to acrolein and crotonaldehyde that might account for these results.

Supporting Information

S1 Table. Median and interquartile range for measures of 3-HPMA and HMPMA, stratified by sex and race/ethnicity.

(DOCX)

S2 Table. Top 100 Associations for 3-HPMA in Overall analysis.

(CSV)

S3 Table. Top 100 Associations for HMPMA in Overall analysis.

(CSV)

S4 Table. Top 100 Associations for 3-HPMA in African Americans.

(CSV)

S5 Table. Top 100 Associations for 3-HPMA among Whites.

(CSV)

S6 Table. Top 100 Associations for 3-HPMA in Native Hawaiians.

(CSV)

S7 Table. Top 100 Associations for 3-HPMA in Latinos.

(CSV)

S8 Table. Top 100 Associations for 3-HPMA in Japanese Americans.

(CSV)

S9 Table. Top 100 Associations for HMPMA in African Americans.

(CSV)

S10 Table. Top 100 Associations for HMPMA in Whites.

(CSV)

S11 Table. Top 100 Associations for HMPMA in Native Hawaiians.

(CSV)

S12 Table. Top 100 Associations for HMPMA in Latinos.

(CSV)

S13 Table. Top 100 Associations for HMPMA in Japanese Americans.

(CSV)

S1 Fig. Quantile-Quantile plot of the GWAS results for 3-HPMA. Genome-wide significance is defined as the Bonferroni corrected 5% significance threshold ($p\text{-value} < 5.0 \times 10^{-8}$).

(JPG)

S2 Fig. Quantile-Quantile plot of the GWAS results for HMPMA. Genome-wide significance is defined as the Bonferroni corrected 5% significance threshold ($p\text{-value} < 5.0 \times 10^{-8}$).

(JPEG)

Acknowledgments

This study was supported by grant no. CA-138338 and in part by grant no. CA-14089 from the U.S. National Cancer Institute (<http://www.cancer.gov>). Mass spectrometry was carried out in the Analytical Biochemistry Shared Resource of the Masonic Cancer Center, supported in part by National Cancer Institute Cancer Center Support grant no. CA-77598.

Author Contributions

Conceived and designed the experiments: SLP DOS CAH LLM SSH. Performed the experiments: SGC MC YP. Analyzed the data: SLP SSH DOS YP. Contributed reagents/materials/analysis tools: SGC MC SSH. Wrote the paper: SLP DOS YP LLM CAH SSH.

References

1. International Agency for Research on Cancer. The Global and Regional Burden of Cancer. In: Stewart BW, Wild CP, editors. World Cancer Report 2014. Lyon, FR: International Agency for Research on Cancer; 2014. pp. 16–53.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. *CA Cancer J Clin*. 2011; 61: 69–90. doi: [10.3322/caac.20107](https://doi.org/10.3322/caac.20107) PMID: [21296855](https://pubmed.ncbi.nlm.nih.gov/21296855/)
3. United States Department of Health and Human Services. The Health Consequences of Smoking: 50 Years of Progress. A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2014.
4. Shafey O, Eriksen MP, Ross H, Mackay J. The Tobacco Atlas, 3rd Edition. Atlanta, GA: American Cancer Society and World Lung Foundation; 2009.
5. Haiman CA, Stram DO, Wilkens LR, Pike MC, Kolonel LN, Henderson BE, et al. Ethnic and racial differences in the smoking-related risk of lung cancer. *N Engl J Med*. 2006; 354: 333–342. PMID: [16436765](https://pubmed.ncbi.nlm.nih.gov/16436765/)
6. Blot WJ, Cohen SS, Aldrich M, McLaughlin JK, Hargreaves MK, Signorello LB. Lung cancer risk among smokers of menthol cigarettes. *J Natl Cancer Inst*. 2011; 103: 810–816. doi: [10.1093/jnci/djr102](https://doi.org/10.1093/jnci/djr102) PMID: [21436064](https://pubmed.ncbi.nlm.nih.gov/21436064/)
7. Gadgeel SM, Severson RK, Kau Y, Graff J, Weiss LK, Kalemkerian GP. Impact of race in lung cancer: analysis of temporal trends from a surveillance, epidemiology, and end results database. *CHEST*. 2001; 120: 55–63. PMID: [11451816](https://pubmed.ncbi.nlm.nih.gov/11451816/)
8. Harris RE, Zang EA, Anderson JI, Wynder EL. Race and sex differences in lung cancer risk associated with cigarette smoking. *Int J Epidemiol*. 1993; 22: 592–599. PMID: [8225730](https://pubmed.ncbi.nlm.nih.gov/8225730/)
9. Hinds MW, Stemmermann GN, Yang HY, Kolonel LN, Lee J, Wegner E. Differences in lung cancer risk from smoking among Japanese, Chinese and Hawaiian women in Hawaii. *Int J Cancer*. 1981; 27: 297–302. PMID: [7287220](https://pubmed.ncbi.nlm.nih.gov/7287220/)
10. Le Marchand L, Wilkens LR, Kolonel LN. Ethnic differences in the lung cancer risk associated with smoking. *Cancer Epidemiol Biomarkers Prev*. 1992; 1: 103–107. PMID: [1306091](https://pubmed.ncbi.nlm.nih.gov/1306091/)
11. Schwartz AG, Swanson GM. Lung carcinoma in African Americans and whites. A population-based study in metropolitan Detroit, Michigan. *Cancer*. 1997; 79: 45–52. PMID: [8988725](https://pubmed.ncbi.nlm.nih.gov/8988725/)
12. Sobue T, Yamamoto S, Hara M, Sasazuki S, Sasaki S, Tsugane S. Cigarette smoking and subsequent risk of lung cancer by histologic type in middle-aged Japanese men and women: the JPHC study. *Int J Cancer*. 2002; 99: 245–251. PMID: [11979440](https://pubmed.ncbi.nlm.nih.gov/11979440/)
13. Stellman SD, Chen Y, Muscat JE, Djordjevic MV, Richie JP Jr, Lazarus P, et al. Lung cancer risk in white and black Americans. *Ann Epidemiol*. 2003; 13: 294–302. PMID: [12684197](https://pubmed.ncbi.nlm.nih.gov/12684197/)

14. Stellman SD, Takezaki T, Wang L, Chen Y, Citron ML, Djordjevic MV, et al. Smoking and lung cancer risk in American and Japanese men: An international case-control study. *Cancer Epidemiol Biomarkers Prev.* 2001; 10: 1193–1199. PMID: [11700268](#)
15. Fast Stats: An interactive tool for access to SEER cancer statistics. Available: <http://seer.cancer.gov/faststats>. Accessed: 2014 Sep 5.
16. Murphy SE, Park S-SL, Thompson EF, Wilkens LR, Patel Y, Stram DO, et al. Nicotine *N*-glucuronidation relative to *N*-oxidation and *C*-oxidation and UGT2B10 genotype in five ethnic/racial groups. *Carcinogenesis.* 2014; 35: 2526–2533. doi: [10.1093/carcin/bgu191](#) PMID: [25233931](#)
17. Patel Y, Stram DO, Wilkens LR, Park SL, Henderson BE, Le Marchand L, et al. The contribution of common genetic variation to nicotine and cotinine glucuronidation in multiple ethnic/racial populations. *Cancer Epidemiol Biomarkers Prev.* 2015; 24: 119–127. doi: [10.1158/1055-9965.EPI-14-0815](#) PMID: [25293881](#)
18. Park SL, Carmella SG, Ming X, Stram DO, Le Marchand L, Hecht SS. Variation in levels of the lung carcinogen NNAL and its glucuronides in the urine of cigarette smokers from five ethnic groups with differing risks for lung cancer. *Cancer Epidemiol Biomarkers & Prev.* 2015; 24: 561–569.
19. Hecht SS, Yuan J-M, Hatsukami DK. Applying tobacco carcinogen and toxicant biomarkers in product regulation and cancer prevention. *Chem Res Toxicol.* 2010; 23: 1001–1008. doi: [10.1021/tx100056m](#) PMID: [20408564](#)
20. Parent RA, Paust DE, Schrimpf MK, Talaat RE, Doane RA, Caravello HE, et al. Metabolism and distribution of [2,3-¹⁴C]acrolein in Sprague-Dawley rats. II. Identification of urinary and fecal metabolites. *Toxicol Sci.* 1998; 43: 110–120. PMID: [9710952](#)
21. International Agency for Research on Cancer. Dry Cleaning, Some Chlorinated Solvents and Other Industrial Chemicals. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans vol. 63. Lyon, France: IARC; 1995. pp. 337–372. PMID: [9139128](#)
22. International Agency for Research on Cancer. Dry Cleaning, Some Chlorinated Solvents and Other Industrial Chemicals. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans vol. 63. Lyon, France: IARC; 1995. pp. 373–391. PMID: [9139128](#)
23. Chung FL, Young R, Hecht SS. Formation of cyclic 1,*N*²-propanodeoxyguanosine adducts in DNA upon reaction with acrolein or crotonaldehyde. *Cancer Res.* 1984; 44: 990–995. PMID: [6318992](#)
24. Minko IG, Kozekov ID, Harris TM, Rizzo CJ, Lloyd RS, Stone MP. Chemistry and biology of DNA containing 1,*N*²-deoxyguanosine adducts of the alpha,beta-unsaturated aldehydes acrolein, crotonaldehyde, and 4-hydroxynonenal. *Chem Res Toxicol.* 2009; 22: 759–778. doi: [10.1021/tx9000489](#) PMID: [19397281](#)
25. Zhang S, Villalta PW, Wang M, Hecht SS. Analysis of crotonaldehyde- and acetaldehyde-derived 1,*N*²-propanodeoxyguanosine adducts in DNA from human tissues using liquid chromatography-electrospray ionization-tandem mass spectrometry. *Chem Res Toxicol.* 2006; 19: 1386–1392. PMID: [17040109](#)
26. Zhang S, Villalta PW, Wang M, Hecht SS. Detection and quantitation of acrolein-derived 1,*N*²-propanodeoxyguanosine adducts in human lung by liquid chromatography-electrospray ionization-tandem mass spectrometry. *Chem Res Toxicol.* 2007; 20: 565–571. PMID: [17385896](#)
27. Feng Z, Hu W, Hu Y, Tang M- S. Acrolein is a major cigarette-related lung cancer agent. Preferential binding at p53 mutational hotspots and inhibition of DNA repair. *Proc Natl Acad Sci USA.* 2006; 103: 15404–15409. PMID: [17030796](#)
28. Hecht SS. Tobacco smoke carcinogens and lung cancer. *J Natl Cancer Inst.* 1999; 91: 1194–1210. PMID: [10413421](#)
29. Kolonel LN, Henderson BE, Hankin JH, Nomura AM, Wilkens LR, Pike MC, et al. A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics. *Am J Epidemiol.* 2000; 151: 346–357. PMID: [10695593](#)
30. Carmella SG, Chen M, Zarth A, Hecht SS. High throughput liquid chromatography-tandem mass spectrometry assay for mercapturic acids of acrolein and crotonaldehyde in cigarette smokers' urine. *J Chromatog B.* 2013; 935: 36–40. doi: [10.1016/j.jchromb.2013.07.004](#) PMID: [23934173](#)
31. Yuan Y. Multiple imputation using SAS software. *J Stat Softw.* 2011; 45: 1–25.
32. Delaneau O, Marchini J, Zagury JF. A linear complexity phasing method for thousands of genomes. *Nat Methods.* 2012; 9: 179–181. doi: [10.1038/nmeth.1785](#) PMID: [22138821](#)
33. Howie BN, Donnelly P, Marchini J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. *PLoS Genet.* 2009; 5: e1000529. doi: [10.1371/journal.pgen.1000529](#) PMID: [19543373](#)
34. Hukkanen J, Jacob P III, Benowitz NL. Metabolism and disposition kinetics of nicotine. *Pharmacol Rev.* 2005; 57: 79–115. PMID: [15734728](#)

35. Hecht SS. Biochemistry, biology, and carcinogenicity of tobacco-specific *N*-nitrosamines. *Chem Res Toxicol*. 1998; 11: 559–603. PMID: [9625726](#)
36. Rivenson A, Hoffmann D, Prokopczyk B, Amin S, Hecht SS. Induction of lung and exocrine pancreas tumors in F344 rats by tobacco-specific and *Areca*-derived *N*-nitrosamines. *Cancer Res*. 1988; 48: 6912–6917. PMID: [3180100](#)
37. Balbo S, Johnson CS, Kovi RC, O'Sullivan MG, Wang M, Le CT, et al. Carcinogenicity and DNA adduct formation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and enantiomers of its metabolite 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol in F-344 rats. *Carcinogenesis*. 2014; 35: 2798–2806. doi: [10.1093/carcin/bgu204](#) PMID: [25269804](#)
38. Carmella SG, Chen M, Han S, Briggs A, Jensen J, Hatsukami DK, et al. Effects of smoking cessation on eight urinary tobacco carcinogen and toxicant biomarkers. *Chem Res Toxicol*. 2009; 22: 734–741. doi: [10.1021/tx800479s](#) PMID: [19317515](#)
39. Mascher DG, Mascher HJ, Scherer G, Schmid ER. High-performance liquid chromatographic-tandem mass spectrometric determination of 3-hydroxypropylmercapturic acid in human urine. *J Chromatogr B Biomed Sci Appl*. 2001; 750: 163–169. PMID: [11204217](#)
40. Yuan JM, Butler LM, Gao YT, Murphy SE, Carmella SG, Wang R, et al. Urinary metabolites of a polycyclic aromatic hydrocarbon and volatile organic compounds in relation to lung cancer development in lifelong never smokers in the Shanghai Cohort Study. *Carcinogenesis*. 2014; 35: 339–345. doi: [10.1093/carcin/bgt352](#) PMID: [24148823](#)
41. Yuan JM, Gao YT, Wang R, Chen M, Carmella SG, Hecht SS. Urinary levels of volatile organic carcinogen and toxicant biomarkers in relation to lung cancer development in smokers. *Carcinogenesis*. 2012; 33: 804–809. doi: [10.1093/carcin/bgs026](#) PMID: [22298640](#)
42. Yan W, Byrd GD, Brown BG, Borgerding MF. Development and validation of a direct LC-MS-MS method to determine the acrolein metabolite 3-HPMA in urine. *J Chromatogr Sci*. 2010; 48: 194–199. PMID: [20223085](#)
43. Schettgen T, Musiol A, Kraus T. Simultaneous determination of mercapturic acids derived from ethylene oxide (HEMA), propylene oxide (2-HPMA), acrolein (3-HPMA), acrylamide (AAMA) and *N,N*-dimethylformamide (AMCC) in human urine using liquid chromatography/tandem mass spectrometry. *Rapid Commun Mass Spectrom*. 2008; 22: 2629–2638. doi: [10.1002/rcm.3659](#) PMID: [18666198](#)
44. Scherer G, Urban M, Hagedorn HW, Feng S, Kinser RD, Sarkar M, et al. Determination of two mercapturic acids related to crotonaldehyde in human urine: influence of smoking. *Hum Exp Toxicol*. 2007; 26: 37–47. PMID: [17334178](#)
45. Counts ME, Hsu FS, Laffoon SW, Dwyer RW, Cox RH. Mainstream smoke constituent yields and predicting relationships from a worldwide market sample of cigarette brands: ISO smoking conditions. *Regul Toxicol Pharmacol*. 2004; 39: 111–134. PMID: [15041144](#)
46. Shepperd CJ, Eldridge AC, Mariner DC, McEwan M, Errington G, Dixon M. A study to estimate and correlate cigarette smoke exposure in smokers in Germany as determined by filter analysis and biomarkers of exposure. *Regul Toxicol Pharmacol*. 2009; 55: 97–109. doi: [10.1016/j.yrtph.2009.06.006](#) PMID: [19539004](#)
47. Roethig HJ, Munjal S, Feng S, Liang Q, Sarkar M, Walk RA, et al. Population estimates for biomarkers of exposure to cigarette smoke in adult U.S. cigarette smokers. *Nicotine Tob Res*. 2009; 11: 1216–1225. doi: [10.1093/ntr/ntp126](#) PMID: [19700523](#)
48. Morin A, Shepperd CJ, Eldridge AC, Poirier N, Voisine R. Estimation and correlation of cigarette smoke exposure in Canadian smokers as determined by filter analysis and biomarkers of exposure. *Regul Toxicol Pharmacol*. 2011; 61: S3–12. doi: [10.1016/j.yrtph.2010.09.020](#) PMID: [20937342](#)
49. Beauchamp RO Jr, Andjelkovich DA, Kligerman AD, Morgan KT, Heck HD. A critical review of the literature on acrolein toxicity. *Crit Rev Toxicol*. 1985; 14: 309–380. PMID: [3902372](#)
50. Bastos LC, Pereira PA. Influence of heating time and metal ions on the amount of free fatty acids and formation rates of selected carbonyl compounds during the thermal oxidation of canola oil. *J Agric Food Chem*. 2010; 58: 12777–12783. doi: [10.1021/jf1028575](#) PMID: [21105653](#)
51. Seaman VY, Bennett DH, Cahill TM. Indoor acrolein emission and decay rates resulting from domestic cooking events. *Atmospheric Environment*. 2009; 43: 6199–6204.
52. Stevens JF, Maier CS. Acrolein: sources, metabolism, and biomolecular interactions relevant to human health and disease. *Mol Nutr Food Res*. 2008; 52: 7–25. doi: [10.1002/mnfr.200700412](#) PMID: [18203133](#)
53. Chung FL, Chen HJC, Nath RG. Lipid peroxidation as a potential source for the formation of exocyclic DNA adducts. *Carcinogenesis*. 1996; 17: 2105–2111. PMID: [8895475](#)

54. Chung FL, Nath RG, Nagao M, Nishikawa A, Zhou GD, Randerath K. Endogenous formation and significance of 1,*N*²-propanodeoxyguanosine adducts. *Mutat Res-Fund Mol M.* 1999; 424: 71–81. PMID: [10064851](#)
55. Sarkar P, Hayes BE. Induction of COX-2 by acrolein in rat lung epithelial cells. *Mol Cell Biochem.* 2007; 301: 191–199. PMID: [17318410](#)
56. Cai J, Bhatnagar A, Pierce WM Jr. Protein modification by acrolein: formation and stability of cysteine adducts. *Chem Res Toxicol.* 2009; 22: 708–716. doi: [10.1021/tx800465m](#) PMID: [19231900](#)
57. Myers CR, Myers JM. The effects of acrolein on peroxiredoxins, thioredoxins, and thioredoxin reductase in human bronchial epithelial cells. *Toxicology.* 2009; 257: 95–104. doi: [10.1016/j.tox.2008.12.013](#) PMID: [19135121](#)
58. Spiess PC, Deng B, Hondal RJ, Matthews DE, van der Vliet A. Proteomic profiling of acrolein adducts in human lung epithelial cells. *J Proteomics.* 2011; 74: 2380–2394. doi: [10.1016/j.jprot.2011.05.039](#) PMID: [21704744](#)
59. Bui LC, Manaa A, Xu X, Duval R, Busi F, Dupret JM, et al. Acrolein, an α,β -unsaturated aldehyde, irreversibly inhibits the acetylation of aromatic amine xenobiotics by human arylamine *N*-acetyltransferase 1. *Drug Metab Dispos.* 2013; 41: 1300–1305. doi: [10.1124/dmd.113.052258](#) PMID: [23633528](#)
60. Wang HT, Hu Y, Tong D, Huang J, Gu L, Wu XR, et al. Effect of carcinogenic acrolein on DNA repair and mutagenic susceptibility. *J Biol Chem.* 2012; 287: 12379–12386. doi: [10.1074/jbc.M111.329623](#) PMID: [22275365](#)
61. Pan J, Awoyemi B, Xuan Z, Vohra P, Wang HT, Dyba M, et al. Detection of acrolein-derived cyclic DNA adducts in human cells by monoclonal antibodies. *Chem Res Toxicol.* 2012; 25: 2788–2795. doi: [10.1021/tx3004104](#) PMID: [23126278](#)
62. Yin R, Liu S, Zhao C, Lu M, Tang MS, Wang H. An ammonium bicarbonate-enhanced stable isotope dilution UHPLC-MS/MS method for sensitive and accurate quantification of acrolein-DNA adducts in human leukocytes. *Anal Chem.* 2013; 85: 3190–3197. doi: [10.1021/ac3034695](#) PMID: [23431959](#)
63. Lee HW, Wang HT, Weng MW, Hu Y, Chen WS, Chou D, et al. Acrolein- and 4-Aminobiphenyl-DNA adducts in human bladder mucosa and tumor tissue and their mutagenicity in human urothelial cells. *Oncotarget.* 2014; 5: 3526–3540. PMID: [24939871](#)
64. Zhang S, Balbo S, Wang M, Hecht SS. Analysis of acrolein-derived 1,*N*²-propanodeoxyguanosine adducts in human leukocyte DNA from smokers and nonsmokers. *Chem Res Toxicol.* 2011; 24: 119–124. doi: [10.1021/tx100321y](#) PMID: [21090699](#)
65. Chung FL, Tanaka T, Hecht SS. Induction of liver tumors in F344 rats by crotonaldehyde. *Cancer Res.* 1986; 46: 1285–1289. PMID: [3002613](#)
66. Chung FL, Hecht SS. Formation of cyclic 1,*N*²-adducts by reaction of deoxyguanosine with α -acetoxy-*N*-nitrosopyrrolidine, 4-(carbethoxynitrosamino)butanal, or crotonaldehyde. *Cancer Res.* 1983; 43: 1230–1235. PMID: [6825094](#)
67. Pan J, Chung FL. Formation of cyclic deoxyguanosine adducts from omega-3 and omega-6 polyunsaturated fatty acids under oxidative conditions. *Chem Res Toxicol.* 2002; 15: 367–372. PMID: [11896684](#)
68. Uchida K, Kanematsu M, Sakai K, Matsuda T, Hattori N, Mizuno Y, et al. Protein-bound acrolein: potential markers for oxidative stress. *Proc Natl Acad Sci U S A.* 1998; 95: 4882–4887. PMID: [9560197](#)
69. Cote F, Letourneau C, Mullard G, Voisine R. Estimation of nicotine and tar yields from human-smoked cigarettes before and after the implementation of the cigarette ignition propensity regulations in Canada. *Regul Toxicol Pharmacol.* 2011; 61: S51–S59. doi: [10.1016/j.yrtph.2010.03.004](#) PMID: [20303374](#)
70. Hee J, Callais F, Momas I, Laurent AM, Min S, Molinier P, et al. Smokers' behaviour and exposure according to cigarette yield and smoking experience. *Pharmacol Biochem Behav.* 1995; 52: 195–203. PMID: [7501665](#)
71. Melikian AA, Djordjevic MV, Hosey J, Zhang J, Chen S, Zang E, et al. Gender differences relative to smoking behavior and emissions of toxins from mainstream cigarette smoke. *Nicotine Tob Res.* 2007; 9: 377–387. PMID: [17365769](#)
72. Berhane K, Mannervik B. Inactivation of the genotoxic aldehyde acrolein by human glutathione transferases of classes alpha, mu, and pi. *Mol Pharmacol.* 1990; 37: 251–254. PMID: [2304453](#)
73. Berhane K, Widersten M, Engstrom A, Kozarich JW, Mannervik B. Detoxication of base propenals and other alpha, beta-unsaturated aldehyde products of radical reactions and lipid peroxidation by human glutathione transferases. *Proc Natl Acad Sci U S A.* 1994; 91: 1480–1484. PMID: [8108434](#)
74. Pal A, Hu X, Zimniak P, Singh SV. Catalytic efficiencies of allelic variants of human glutathione S-transferase Pi in the glutathione conjugation of alpha, beta-unsaturated aldehydes. *Cancer Lett.* 2000; 154: 39–43. PMID: [10799737](#)

75. Conklin DJ, Haberzettl P, Lesgards JF, Prough RA, Srivastava S, Bhatnagar A. Increased sensitivity of glutathione S-transferase P-null mice to cyclophosphamide-induced urinary bladder toxicity. *J Pharmacol Exp Ther*. 2009; 331: 456–469. doi: [10.1124/jpet.109.156513](https://doi.org/10.1124/jpet.109.156513) PMID: [19696094](https://pubmed.ncbi.nlm.nih.gov/19696094/)